Candidemia Market

Market Overview:

The 7 major candidemia markets are expected to exhibit a CAGR of 3.16% during 2024-2034.

The candidemia market has been comprehensively analyzed in IMARC's new report titled "Candidemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Candidemia is a serious medical condition characterized by the presence of Candida species, particularly Candida albicans, in the bloodstream. These are typically harmless fungi found on the mucous membranes and skin, but when they enter the bloodstream, they can cause severe infections. The indications of the ailment can vary widely, ranging from mild to severe. Some common manifestations include fever, chills, rapid heartbeat, and low blood pressure. Individuals suffering from this ailment may also experience general malaise, confusion, and discomfort at the site of a catheter, if one is present. Since these symptoms are non-specific and can resemble those of various other infections, diagnosing candidemia requires a combination of clinical findings and laboratory tests. Physicians might also perform blood cultures, which involve growing and identifying the Candida species from a blood sample, to confirm the diagnosis. This disease can rapidly progress and cause life-threatening complications; hence, early detection and prompt treatment of candidemia are essential.

The increasing cases of weakened immune systems due to conditions like HIV/AIDS, cancer, organ transplants, etc., are primarily driving the candidemia market. In addition to this, the inflating utilization of efficacious treatments, such as antifungal medications, including azoles, echinocandins, polyenes, etc., to effectively manage the infection and slow down its progression, is also creating a positive outlook for the market. Moreover, the widespread adoption of preventative measures and infection control protocols in healthcare settings, given their instrumental role in reducing the risk of disease contraction, is also contributing to the augmentation of the market. Apart from this, the rising usage of advanced diagnostic techniques, such as molecular assays and biomarker identification, for swift and accurate detection of candidemia is acting as another significant growth-inducing factor. These tools enable timely intervention and tailored treatment strategies, thereby enhancing patient outcomes. Additionally, the escalating focus on research and development activities to better understand the underlying pathways of fungal infections and explore potential therapeutic medications to treat severe disease conditions is also augmenting the market growth. Furthermore, the emerging popularity of innovative treatment modalities, including novel drug formulations and immune-based therapies, which aim to offer enhanced efficacy and reduced adverse effects, is expected to drive the candidemia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the candidemia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for candidemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the candidemia market in any manner.

Recent Developments:

• In January 2024, Cidara Therapeutics, Inc. announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom (U.K.) approved REZZAYO (rezafungin acetate) for the management of invasive candidiasis in adults. REZZAYO is a new once-weekly echinocandin licensed in the United States to treat candidemia and invasive candidiasis in adults.
• In November 2023, Basilea Pharmaceutica Ltd stated that it had signed an asset purchase agreement with Amplyx Pharmaceuticals, Inc., a Pfizer Inc. company, to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate. Additionally, Basilea has purchased the rights to a preclinical antifungal chemical.
• In July 2023, T2 Biosystems, Inc. declared that the US Food and Drug Administration (FDA) granted Breakthrough Device status for the Company's Candida auris (C. auris) direct-from-blood molecular diagnostic test.
• In March 2023, the FDA approved Melinta Therapeutics' and Cidara Therapeutics' Rezzayo (rezafungin acetate) for the treatment of candidemia and invasive candidiasis in individuals who have limited or no other therapeutic choices. REZZAYO is the first new therapy option approved for candidemia and invasive candidiasis in over 15 years.

Key Highlights:

• Candidemia is one of the most frequent bloodstream infections in the United States, with an average incidence of around 9 per 100,000 persons.
• The CDC estimates that roughly 25,000 cases of candidemia occur nationwide every year.
• As per the findings of the American Thoracic Society, candidemia causes approximately 10% of nosocomial bloodstream infections, making it the most common dangerous mold infection in United States inpatient settings.
• Candidemia rates are around twice as high among Black people as they are among other races/ethnicities, regardless of age.
• According to the Centers for Disease Control and Prevention, up to 25,000 instances of severe candidiasis in the kidneys, bones, and other internal organs go undiscovered annually.
• An estimated 33-55% of all candidemia episodes occur in intensive care units (ICU), with fatality rates ranging from 5% to 71%.

Drugs:

REZZAYO (rezafungin for injection) is a new once-weekly echinocandin authorized in the United States to treat candidemia and invasive candidiasis in adults. The drug has a unique pharmacokinetic profile with an extended half-life and front-loaded plasma exposure, which, in contrast to all other echinocandins, allows for once-weekly IV therapy for inpatient and outpatient use.

Anidulafungin is a semi-synthetic echinocandin with antifungal properties. Anidulafungin inhibits the enzyme glucan synthase, which is found in fungal but not mammalian cells. This inhibits the synthesis of 1,3-β-D-glucan, a key component of the fungal cell wall, resulting in osmotic instability and cell death.

Fosmanogepix is a potential first-in-class antifungal therapy with a new mode of action. It is available in intravenous and oral formulations. It has been tested for efficacy and safety in phase 1 / phase 2 program, including three open-label phase 2 studies for the treatment of Candida auris and invasive mold infections.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the candidemia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the candidemia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current candidemia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the candidemia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the candidemia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the candidemia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of candidemia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of candidemia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of candidemia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with candidemia across the seven major markets?
• What is the size of the candidemia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of candidemia?
• What will be the growth rate of patients across the seven major markets?
   

Candidemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for candidemia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the candidemia market?
• What are the key regulatory events related to the candidemia market?
• What is the structure of clinical trial landscape by status related to the candidemia market?
• What is the structure of clinical trial landscape by phase related to the candidemia market?
• What is the structure of clinical trial landscape by route of administration related to the candidemia market?